20/01/2021
Bioequivalence testing is an essential step during the development of generic drugs. Despite recommendations and guidelines from Regulatory authorities on the methodology, there is no consensus and statistical approaches differ...
Continue Reading
07/12/2021
Raphaële Audibert, Global Category Manager, Inhalation & Dermal, Mark Tunkel, Global Category Director, Services, and Manuela Basso, Communications Manager, all at Nemera, look at the role patient-centricity has to ...
Continue Reading
23/11/2021
Severine Duband, our Marketing Director was interviewed by the journalist of the 'Pharmaceutical Post', to talk about Symbioze and how we developed the product. The main challenge for manufacturers is...
Continue Reading
30/09/2021
TACKLING HIGH-VOLUME ADMINISTRATION CHALLENGES WITH A SMART, SUSTAINABLE ON-BODY INJECTOR PLATFORM In this article, Séverine Duband, Marketing Director, Drug Delivery Devices at Nemera, introduces Symbioze, Nemera’s novel on-body ...
Continue Reading
02/09/2021
Between-Batch Bioequivalence (BBE): An Alternative Statistical Method to Assess In Vitro Bioequivalence of Nasal Product INTRODUCTION In the pharmaceutical industry, we can see the development of generics is significantly growing....
Continue Reading
05/06/2021
A new statistical method to assess in vitro bioequivalence of nasal products Bioequivalence testing is an essential step during the development of ...
Continue Reading